Taro shareholders approved merger with Sun Pharma
The merger was approved at meetings on May 22, 2024, and is expected to close in about 35 days, pending conditions.
Latest Taro Pharmaceutical Industries News & Updates
See the latest news and media coverage for Taro. We track all announcements, press releases, and industry mentions in real time, all in one place.
Generic pharmaceutical and consumer healthcare company
taro.com- Headquarters
- United States
- Company type
- Public company
- Number of employees
- 1,200–5,000
Last updated
Latest news about Taro Pharmaceutical Industries (Taro)
In short: Taro Pharmaceutical Industries moved toward a merger with Sun Pharma and reported Q4 earnings while facing a safety recall and legal scrutiny.
Company announcements
Taro announces merger agreement with Sun Pharma
Sun Pharma will acquire all outstanding Taro shares for US$43.00 per share in cash.
Taro Pharma announces USFDA approval for generic Prevacid
The generic lansoprazole delayed-release capsules are approved by the FDA.
Taro announces USFDA approval for generic Depo-Testosterone Injection
This approval allows Taro to market a generic alternative to Depo-Testosterone Injection.
Media coverage
Sun Pharma's Taro recalls over 17,000 units of antifungal shampoo in US amid safety concerns
Taro Pharmaceutical Industries, a unit of Sun Pharma, is recalling over 17,000 units of an antifungal medication in the US due to manufacturing issues, according...
Taro Pharma Beats Investor Suit Over $43-Per-Share Buyout - Law360
A New York federal judge tossed a proposed class action brought by minority shareholders of Taro Pharmaceutical Industries Ltd. that alleged the company and its...
TARO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class ...
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased...
TARO Stock Earnings: Taro Pharmaceutical Indus Reported Results for Q4 2024
Taro Pharmaceutical Indus (NYSE:TARO) just reported results for the fourth quarter of 2024. Taro Pharmaceutical Indus reported earnings per share of 43 cents. The company...
Never miss news about Taro
Track Taro and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Taro competitors & trending companies
Browse news for competitors to Taro and other trending companies.